Y-Biologics, Inc.
Research Y-Biologics, Inc. (338840.KQ) on Bullrun: market cap KRW 110.18B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker338840.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 110.18B
- Financial periodQ2 2026
- RevenueKRW 1.55B
- Net income-KRW 7.83B
- Free cash flow-KRW 3.26B
- Gross margin90.5%
Valuation Snapshot
latest market cap is KRW 110.18B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 110.18B | n/a | n/a | n/a |
Dividend history
About Y-Biologics, Inc.
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Y-Biologics, Inc.'s market cap?
Y-Biologics, Inc.'s market capitalization is KRW 110.18B.
What does Y-Biologics, Inc. do?
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 and is headquartered in Daejeon, South Korea.